Evan Seigerman, an analyst from BMO Capital, maintained the Buy rating on Vertex Pharmaceuticals. The associated price target remains the same with $530.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Evan Seigerman has given his Buy rating due to a combination of factors including the promising growth trajectory of Vertex Pharmaceuticals’ new product, Journavx, which is used for treating acute pain. The weekly script tracker indicates a steady increase in both total and new prescriptions, reflecting strong market uptake and potential for significant revenue contribution in the latter half of 2025.
Additionally, Vertex’s management has been proactive in ensuring a successful product launch by securing broad coverage, enhancing physician awareness, and ensuring product availability. Furthermore, the company’s robust pipeline, particularly in cystic fibrosis and promising developments in other areas such as type 1 diabetes, supports the potential for share price appreciation. These factors collectively underpin Seigerman’s confidence in the company’s growth prospects and justify the Buy rating.
In another report released on August 28, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $438.00 price target.
VRTX’s price has also changed moderately for the past six months – from $491.640 to $396.120, which is a -19.43% drop .